Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
For prophylaxis of asthma by inhalation of powder
• Child 12–17 years: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained.
• Adult: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained.
For prophylaxis of severe asthma by inhalation of powder
• Child 12–17 years: Increased if necessary up to 400 micrograms twice daily.
• Adult: Increased if necessary up to 400 micrograms twice daily.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
For prophylaxis of asthma by inhalation of powder
• Child 12–17 years: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained.
• Adult: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained.
For prophylaxis of severe asthma by inhalation of powder
• Child 12–17 years: Increased if necessary up to 400 micrograms twice daily.
• Adult: Increased if necessary up to 400 micrograms twice daily.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
Long-acting selective beta2 agonist, long-acting muscarinic antagonist with corticosteroid.
Adult: one inhalation once daily.
A leukotriene receptor antagonist that inhibits bronchoconstriction by blocking the inflammatory response in the airways.
Prophylaxis of asthma
• Child 6 months–5 years: 4 mg once daily in the evening.
• 6–14 years: 5 mg once daily in the evening
• Adult and child over 15 years: 10 mg once daily in the evening
Seasonal allergic rhinitis in patients with asthma
• Adult and child over 15 years: 10 mg once daily in the evening